Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.49 |
| ▸ | AKT1 | P31749 | 4/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.31 |
| ▸ | CDC42BPB | Q9Y5S2 | 3/20 | 0.31 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334699 | 0.93 | CPB2 (0.56) | CPB2AKT1 | |
| SCHEMBL6324378 | 0.93 | CPB2 (0.56) | CPB2AKT1 | |
| SCHEMBL6324387 | 0.93 | CPB2 (0.56) | CPB2AKT1 | |
| SCHEMBL8363717 | 0.80 | CPB2 (0.45) | CPB2AKT1 | |
| SCHEMBL3843654 | 0.77 | OPRD1 (0.35) | CPB2 | |
| SCHEMBL27593612 | 0.76 | LMNA (0.37) | CPB2 | |
| SCHEMBL3838880 | 0.76 | LMNA (0.37) | CPB2 | |
| Trifluoroacetic Acid SCHEMBL6327175 | 0.76 | CPB2 (0.43) | CPB2AKT1 | |
| Histidine SCHEMBL5491748 | 0.74 | SLC7A5 (0.38) | CPB2 | |
| Histidine SCHEMBL5491744 | 0.74 | SLC7A5 (0.38) | CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003061653-A1 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |